in Health care
Merck to acquire Prometheus Biosciences for USD 11 billion
Rahway: Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. have announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. “At Merck, we […] More
